Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
FOXO4-DRI is amino acids long, whereas PT-141 is longer as it has a length of 7 amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. PT-141 is made up of a sequence of sequence data not available in the current dataset.
FOXO4-DRI
FOXO4
PT-141
POMC
No related articles are linked to these peptides yet.